730 results on '"Cenci M"'
Search Results
2. Electronic waste in emerging countries: current scenario of generation, policies, and recycling technologies regarding the coronavirus pandemic
3. Cells, pathways, and models in dyskinesia research
4. Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
5. Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia
6. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
7. D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease
8. Structural‐functional properties of direct‐pathway striatal neurons at early and chronic stages of dopamine denervation.
9. Structural‐functional properties of direct‐pathway striatal neurons at early and chronic stages of dopamine denervation
10. Portable EDXRF spectrometer: determination of linearity, LOD, LOQ, and working range for the analysis of base and precious metals in liquid matrices
11. BIOÉTICA NAS PROFISSÕES: Ciências Humanas Série Bioética – Volume 11
12. Toxin-Based Rodent Models of Parkinson’s Disease
13. Animal models for preclinical Parkinson's research: An update and critical appraisal
14. Preface: The evolving scenario of Parkinson's research
15. The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications
16. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
17. Electronic waste in emerging countries: current scenario of generation, policies, and recycling technologies regarding the coronavirus pandemic
18. Signaling Mechanisms in l-DOPA-Induced Dyskinesia
19. On the neuronal circuitry mediating l-DOPA-induced dyskinesia
20. Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice
21. Preclinical Models of Levodopa-Induced Dyskinesia
22. Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa ‐Induced Dyskinesia
23. Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia
24. Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse
25. Dopamine Replacement Therapy in Parkinson’s Disease: Past, Present and Future
26. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia
27. Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats
28. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action
29. A Genetic Mouse Model of Parkinson’s Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine
30. Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism
31. Maternal attitudes towards tooth decay in children aged 12–18 months in Pelotas, Brazil
32. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease
33. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
34. Non-Apoptotic Caspase-3 Activation Mediates Early Synaptic Dysfunction of Indirect Pathway Neurons in the Parkinsonian Striatum
35. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa—induced dyskinesia
36. La valutazione del risarcimento del danno da mancata OPA
37. ENSINO AFETIVO DA TEOLOGIA E EMPATIA EM EDITH STEIN
38. Failed Bonded Interfaces Submitted to Microcosm Biofilm Caries Development: 92
39. Contributors
40. Rodent Models of Treatment-Related Complications in Parkinson Disease
41. Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
42. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinsonʼs disease
43. NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
44. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia
45. Rodent models of treatment-induced motor complications in Parkinson's disease
46. Targeting angiogenesis in advanced non-small-cell lung cancer: are biomarkers needed?
47. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
48. Preclinical evaluation of selective 5-HT1A biased agonists in the rat model of L-DOPA-induced dyskinesia: 364
49. Neurorestorative effects of a selective sigma-1 receptor agonist in experimental parkinsonism: 359
50. Pharmacological investigation on the mechanisms mediating increases in regional cerebral blood flow in L-DOPA induced dyskinesia: 349
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.